Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03974932 · ClinicalTrials.gov registry record · Phase 3

Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen

A Phase 3 study, sponsored by Heron Therapeutics.

Completed
Registry status
Phase 3
Development phase
116
Enrollment target

NCT03974932 is a Phase 3 study that has completed, run by Heron Therapeutics. The registered enrollment target is 116 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03974932, a Phase 3 study, has completed, sponsored by Heron Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
116 participants
Enrollment target

Study Summary

Phase 3b, open-label single-arm study in which all subjects receive HTX-011 as part of a scheduled non-opioid MMA regimen.

Interventions

  • DRUG Acetaminophen
  • DRUG Ibuprofen
  • DRUG Celecoxib
  • DRUG HTX-011
  • DRUG +/- Bupivacaine HCl

Trial Details

FieldValue
Enrollment Target 116 participants
Start Date 2019-06-05
Est. Completion 2021-01-07
Phase Phase 3

Sponsor

Heron Therapeutics

23 total trials

What the Registry Record Tells You About NCT03974932

The ClinicalTrials.gov registry entry for NCT03974932 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heron Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Acetaminophen is the first listed.

NCT03974932 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03974932 about?

NCT03974932 is a clinical study titled "Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen". Phase 3b, open-label single-arm study in which all subjects receive HTX-011 as part of a scheduled non-opioid MMA regimen.

What is the current status of trial NCT03974932?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 2019-06-05. Estimated completion is 2021-01-07.

What interventions are being tested in trial NCT03974932?

The interventions under investigation include: Acetaminophen (DRUG), Ibuprofen (DRUG), Celecoxib (DRUG), HTX-011 (DRUG), +/- Bupivacaine HCl (DRUG).

Who is sponsoring clinical trial NCT03974932?

This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.